A carregar...
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious s...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2785832/ https://ncbi.nlm.nih.gov/pubmed/19909541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-46 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|